UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 1

of 'Evaluation and treatment of antibody-mediated lung transplant rejection'

1
TI
Acute allograft rejection: cellular and humoral processes.
AU
Martinu T, Pavlisko EN, Chen DF, Palmer SM
SO
Clin Chest Med. 2011 Jun;32(2):295-310. Epub 2011 Mar 25.
 
Acute cellular rejection affects greater than one-third of lung transplant recipients. Alloreactive T-lymphocytes constitute the basis of lung allograft rejection. Recent evidence supports a more complex immune response to the allograft. Interaction between recipient genetics, immunosuppression therapies, and allograft environmental exposures likely contribute to high rejection rates after lung transplantation. A greater understanding of the heterogeneous mechanisms of lung rejection is critical to developing effective therapies that target the precise pathophysiology of the disease and ultimately improve long-term lung transplant outcomes.
AD
Lung and Heart-Lung Transplant Program, Division of Pulmonary and Critical Care, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. tereza.martinu@duke.edu
PMID